Navigation Links
Shire Continues to Deliver Excellent Growth From Core Products
Date:10/30/2009

les in the mid-teens range on average between 2009 and 2015.

Following US approval of INTUNIV, our new ADHD treatment, we are preparing for the US launch next week. INTUNIV adds a new choice of treatment for physicians and patients within our market-leading branded portfolio of ADHD products. We have also continued to grow VYVANSE's market share which is now 13.4%, benefiting from both the 'back to school' season and strong 10% ADHD market growth. These results reinforce our confidence that VYVANSE will grow to become a leading product in this market.

Our HGT business continues to deliver; a New Drug Application for velaglucerase alfa, for Gaucher disease, was filed with the FDA at the end of August. Velaglucerase alfa is available ahead of its commercial launch in the US via a treatment protocol and elsewhere on a pre-approval access basis. We are supporting the Fabry disease community with a stronger uptake of REPLAGAL in Europe. In the US a treatment protocol has been approved, enabling immediate access to the drug. In addition we plan to file a Biologics License Application with the FDA for REPLAGAL by the end of the year.

We continue to invest in our R&D pipeline. This quarter we announced a research collaboration with Santaris Pharma A/S, a leading player in RNA-based therapeutics, to develop its proprietary Locked Nucleic Acid technology in a range of rare diseases, thereby enabling us to build on our already strong competitive position in this area."

    Third Quarter 2009 Unaudited Results

                             Q3 2009                     Q3 2008

                        US   Adjust-               Non   Adjust-      Non
                      GAAP    ments   GAAP(1)  US GAAP    ments    GAAP(1)
                        $M       $M       $M        $M       $M        $M

    Revenues           667        -      667       779        -       779
    Operating income    92       42      134    
'/>"/>
SOURCE  Shire Plc
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 

Related medicine technology :

1. Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients
2. Shire Enhances its Orphan Drug Pipeline With the Acquisition of a New Clinical Candidate for Metachromatic Leukodystrophy
3. Shire to Present Additional Scientific Data on ADHD Treatment Portfolio at American Psychiatric Association Annual Meeting
4. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
5. Shire Announces Approval of ELAPRASE(R) (idursulfase) in Brazil
6. Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent
7. Shire Withdraws European Application for DAYTRANA(TM) (Methylphenidate Transdermal System)
8. Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms
9. Shire Presented Results of a New Database Analysis on Lialda(R) (Mesalamine) and Other 5-ASAs for Ulcerative Colitis at Digestive Disease Week
10. Shire has Filed a Treatment Protocol for Velaglucerase Alfa for Gaucher Disease
11. Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)...  Lakeland Industries, Inc. (NASDAQ: LAKE ), ... healthcare and to first responders on the federal, state ... the fiscal 2013 fourth quarter and year ended January ... market close and will conduct a conference call on ... (Logo: http://photos.prnewswire.com/prnh/20120611/NY21959LOGO ) The call ...
(Date:5/17/2013)... DIEGO and CAMBRIDGE, Mass., May 17, 2013 /PRNewswire/ ... that a purchaser of Aveo Pharmaceutical, Inc. (NASDAQGS: AVEO) ... Court for the District of Massachusetts ... its officers violated the Securities Exchange Act of 1934 ... 1, 2013 (the "Class Period"). (Logo: ...
(Date:5/17/2013)... -- Research explores data on treatments ...   to   be presented Shire ... global specialty biopharmaceutical company, announces that it will present ... Psychiatric Association (APA) 166th Annual Meeting in ... presented represent Shire,s ongoing commitment to the clinical research ...
Breaking Medicine Technology:Lakeland Industries to Report Fiscal Fourth Quarter and Year End Financial Results and Conduct Conference Call 2Aveo Pharmaceuticals, Inc. Sued by Investor 2Aveo Pharmaceuticals, Inc. Sued by Investor 3Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 2Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 3Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 4Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 5Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 6Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 7Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 8Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 9Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 10
... NEW YORK, Feb. 27, 2012 Delcath Systems, Inc., ... first patients in Germany have been treated with the ... Johann Wolfgang Goethe University Hospital, a premier European cancer treatment ... as part of the initial launch and training agreement ...
...  Osseon ® Therapeutics, Inc. announced today that ... Agreement with Aesculap AG to distribute its vertebral ... CE-Mark approved device – Osseoflex ® SB ... Asia.  Aesculap is a division of B. Braun ...
Cached Medicine Technology:Delcath Announces First CHEMOSAT Procedures in Germany 2Delcath Announces First CHEMOSAT Procedures in Germany 3Delcath Announces First CHEMOSAT Procedures in Germany 4Osseon® Announces International Distribution Agreement with Aesculap 2
(Date:5/18/2013)... 2013 As metal-on-metal hip implant ... country, Bernstein Liebhard LLP notes that a new study ... tissue damage before they experience any pain from a ... Daily will appear in the Journal of Bone & ... screens of their hips. The researchers found tissue ...
(Date:5/18/2013)... (PRWEB) May 18, 2013 Simple changes ... in healthy snacks and drinking more water can lead ... and, ultimately, a healthier lifestyle overall. Diet Doc ... the best weight loss can be difficult and often ... their diet plans to help patients get over initial ...
(Date:5/18/2013)... Florida (PRWEB) May 18, 2013 Adolescents, ... also known as “Spice” or “K2” are landing in ... helping to curb this drug epidemic with a ... synthetic marijuana. , According to research from the National ... second-most popular illegal drug among American teenagers. In 2012, ...
(Date:5/18/2013)... CA (PRWEB) May 18, 2013 The ... for 2013 therapies. At the Ayurvedic Spa , ... of panchakarma practitioner and lifestyle recommendations and ... the “knowledge of life", is the traditional healthcare system ... a life of harmony is the basis for all ...
(Date:5/18/2013)... Losing weight remains to be the biggest challenge for ... weight loss products available in the market today, Garcinia Cambogia ... newest weight loss supplement prove that dieting and exercising aren’t ... is a sub-tropical fruit that is shaped like a pumpkin ... a person’s appetite, while it effectively burns fat at the ...
Breaking Medicine News(10 mins):Health News:Metal-on-Metal Hip Implants: Bernstein Liebhard LLP Comments on New Study Finding that Tissue Damage Precedes Pain in Metal-on-Metal Hip Replacement Patients 2Health News:Metal-on-Metal Hip Implants: Bernstein Liebhard LLP Comments on New Study Finding that Tissue Damage Precedes Pain in Metal-on-Metal Hip Replacement Patients 3Health News:Metal-on-Metal Hip Implants: Bernstein Liebhard LLP Comments on New Study Finding that Tissue Damage Precedes Pain in Metal-on-Metal Hip Replacement Patients 4Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Announce the Best Weight Loss Through New Whole Foods, Healthy Snacks and Prescription Strength hCG Treatments 2Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Announce the Best Weight Loss Through New Whole Foods, Healthy Snacks and Prescription Strength hCG Treatments 3Health News:Spice Addiction Treatment and Synthetic Marijuana Drug Rehab Announced by Recovery Associates 2Health News:Ayurveda Spa Treatments Now Offered at the California College of Ayurveda Panchakarma Center 2Health News:Lose Weight Without Dieting or Exercising with Garcinia Cambogia Select Now Available At HealthCareSupplementz.com 2
... HealthDay Reporter , MONDAY, Dec. 12 (HealthDay News) -- Toddlers ... finding that researchers say may provide a clue to the ... is largely an involuntary process that helps keep the eyes ... are closed, you are temporarily blinded. And throughout a typical ...
... infrastructure, inefficient distribution channels and disruptive black markets must ... with the growing problem of malaria, according to a ... Systems and Management . Historically, malaria is humanity,s ... some regions it remains the biggest infectious threat in ...
... , MONDAY, Dec. 12 (HealthDay News) -- Acupuncture may ... according to a new study. Cancer drugs called ... nerves, especially in the calves and feet, resulting in ... is no effective treatment for the condition, called chemotherapy ...
... Reporter , MONDAY, Dec. 12 (HealthDay News) -- When she was ... Madeline Mann was the world,s smallest surviving baby. At the ... world,s tiniest infant, weighing in at 0.57 pounds. She was one ... the neonatal intensive care unit at Loyola University Medical Center in ...
... Reinberg HealthDay Reporter , MONDAY, Dec. 12 ... colon, breast, prostate and cervical cancer even though guidelines ... finds. As the population of the United States ... will be a continuing battle, experts say. "In an ...
... Patients who receive a blood ... to treat leukemia and other blood diseases are more likely ... disease, a condition caused by the donor cells attacking the ... a donor,s bone marrow, rather than from blood stem cells ...
Cached Medicine News:Health News:Blink Patterns May Be a Window Into Autistic Mind 2Health News:Blink Patterns May Be a Window Into Autistic Mind 3Health News:A logistics approach to malaria in Africa 2Health News:Acupuncture Might Ease Chemotherapy Pain 2Health News:World's Tiniest 'Preemies' Growing Up Healthy: Report 2Health News:World's Tiniest 'Preemies' Growing Up Healthy: Report 3Health News:Are Too Many Older People Screened for Cancer? 2Health News:Are Too Many Older People Screened for Cancer? 3Health News:Bone marrow and blood stem cell transplant survival rates equal, when donor is unrelated to patient 2
... high gel strength, high electrophoretic mobility, ... agarose is the superior choice for ... remain easy to handle at concentrations ... shorter run times. Low background staining ...
... This new general-purpose agarose, like the ... quality tested (GQT) grade. This ensures that ... be manipulated without compromising quality. Certified molecular ... a very high molecular weight, resulting in ...
... of a set of reagents and instruments ... in hospital immunohematology labs and blood transfusion ... solutions in robotics, fluidics or the analysis ... monoclonal antibodies and the human antiglobulin reagents ...
A custom blend for Applied Biosystems by FMC. Designed specifically for the electrophoresis of PCR products....
Medicine Products: